Patent Applications Approved in Canada, the European Union & Japan

MISSISSAUGA, Ontario - February 22, 2011 - CardioGenics Holdings Inc. (CGNH.OB) announced today that it has been notified by the Canadian Intellectual Property Office that its patent application for the "core technology" utilized in its ultra-sensitive point-of-care immuno-analyzer, the QL Care™ Analyzer, has been granted. Patents covering the "core technology" have now been issued in Canada, the European Union and Japan. A patent application for the "core technology" is currently pending in the U.S. before the United States Patent & Trademark Office (USPTO).

Yahia Gawad, MD, Chief Executive Officer of CardioGenics Holdings Inc. said, "We are very pleased that the patent offices of Canada, the European Union and Japan have acknowledged the unique nature of the 'core technology' upon which our QL Care™ Analyzer is based."

"The granting of these patents in these major commercial markets further enhances the value of CardioGenics' intellectual property portfolio and we now look forward to a similar disposition of our patent application for the 'core technology' from the USPTO," continued Dr. Gawad.